What does this research mean for the field?

Simultaneous in vivo engineering of both innate (myeloid, NK) and adaptive (T) immune cells using cell-specific CAR mRNA lipid nanoparticles produces potent anti-tumor activity and tumor regression in solid cancers. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.ESTABLISHES_NEW_DIRECTION.

What question did this study set out to answer?

The aim is to develop a strategy for enhancing the anti-tumor response by engineering both adaptive and myeloid immune cells using CAR mRNA.

April 5, 2026Cancer Research

In Vivo CAR mRNA Engineering Enhances Anti-Tumor Responses of Immune Cells

View Full Paper

Ask AI

Bookmark

Authors

JTJunming Tong MCMoore Chen KSKevin Sek

Discussion

Member takes

Overview

In vivo CAR mRNA engineering improves anti-tumor efficacy in solid cancers, suggesting a new therapeutic strategy.

Key Points

The aim is to develop a strategy for enhancing the anti-tumor response by engineering both adaptive and myeloid immune cells using CAR mRNA.
Utilized anti-HER2 CAR mRNAs optimized for different immune cell types.
Encapsulated mRNA in lipid nanoparticles (LNPs) for intravenous delivery.
Evaluated anti-tumor effects in immunocompetent hHER2 transgenic mice with colon adenocarcinoma.
Combined engineering of NK cells, myeloid cells, and T cells with tailored CAR architectures.
Myeloid and NK cell reprogramming drove significant tumor regression and prolonged survival.
Enhanced T-cell activation and infiltration into the tumor microenvironment.
Co-delivery of CAR mRNA to myeloid and T-cell compartments achieved superior anti-tumor control.

Cite This Study

Tong et al. (2026) studied this question.

synapsesocial.com/papers/69d1fca7a79560c99a0a2388 https://doi.org/10.1158/1538-7445.am2026-144

View Full Paper

Ask AI

Bookmark

April 5, 2026Cancer Research

In Vivo CAR mRNA Engineering Enhances Anti-Tumor Responses of Immune Cells

View Full Paper

Ask AI

Bookmark

Authors

JTJunming Tong MCMoore Chen KSKevin Sek

Discussion

Member takes

Overview

In vivo CAR mRNA engineering improves anti-tumor efficacy in solid cancers, suggesting a new therapeutic strategy.

Key Points

The aim is to develop a strategy for enhancing the anti-tumor response by engineering both adaptive and myeloid immune cells using CAR mRNA.
Utilized anti-HER2 CAR mRNAs optimized for different immune cell types.
Encapsulated mRNA in lipid nanoparticles (LNPs) for intravenous delivery.
Evaluated anti-tumor effects in immunocompetent hHER2 transgenic mice with colon adenocarcinoma.
Combined engineering of NK cells, myeloid cells, and T cells with tailored CAR architectures.
Myeloid and NK cell reprogramming drove significant tumor regression and prolonged survival.
Enhanced T-cell activation and infiltration into the tumor microenvironment.
Co-delivery of CAR mRNA to myeloid and T-cell compartments achieved superior anti-tumor control.

Cite This Study

Tong et al. (2026) studied this question.

synapsesocial.com/papers/69d1fca7a79560c99a0a2388 https://doi.org/10.1158/1538-7445.am2026-144

View Full Paper

Ask AI

Bookmark